Luc Van Gaal
University of Antwerp · 224 works · 18,760 citations · h-index 67
Top works
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
- International Day for the Evaluation of Abdominal Obesity (IDEA)
- Depot-Specific Differences in Adipose Tissue Gene Expression in Lean and Obese Subjects
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
- Body surface area in normal-weight, overweight, and obese adults. A comparison study
- Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
- The Effect of Exercise on Visceral Adipose Tissue in Overweight Adults: A Systematic Review and Meta-Analysis
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- Intensive Insulin Therapy in the Intensive Care Unit
- Variants in the FTO gene are associated with common obesity in the Belgian population
- Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors’ Expert Forum
- Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
- Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial
- PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis